Breaking the Cycle: Cost-Plus vs. Spread Pricing in Pharmacy Benefits

For years, the pharmacy benefit industry has operated under a veil of complexity that makes it difficult for employers and brokers to determine if they are getting a fair deal. At the heart of this confusion are two competing financial models: Spread Pricing and Cost-Plus Pricing. While one relies on hidden margins and misaligned incentives, the other offers a path toward transparency and fiduciary responsibility.

Understanding these two models is essential for any broker looking to move their clients away from the “black box” of traditional PBMs and toward sustainable expense optimization.

Spread Pricing: The Hidden Margin Model

In a spread pricing model, the Pharmacy Benefit Manager (PBM) acts as a middleman that profits from the difference (the “spread”) between what they pay the pharmacy and what they charge the employer.

Because the PBM is not required to disclose the actual acquisition cost of the drug, the “spread” remains invisible to the plan sponsor. This creates several structural issues:

• Misaligned Incentives: The PBM is financially motivated to favor higher-cost drugs because a larger price tag often allows for a larger hidden spread.
• The “Discount” Illusion: PBMs often market “steep discounts” off the Average Wholesale Price (AWP). However, if the spread is wide enough, the employer still pays significantly more than the drug’s actual value.
• Lack of Accountability: Since the employer never sees the pharmacy’s actual reimbursement rate, it is impossible to verify if the plan is truly achieving cost containment.

Cost-Plus Pricing: The Transparent Alternative

Cost-plus pricing is designed to eliminate the middleman’s hidden margins. In this model, the employer pays the actual cost the pharmacy paid to acquire the drug, plus a flat, pre-negotiated dispensing fee and an administrative fee.

This shift in math changes the entire dynamic of the pharmacy benefit:

• Total Transparency: Every dollar is accounted for. The employer knows exactly what the drug costs and exactly what they are paying the PBM for their services.
• Fiduciary Alignment: Because the PBM’s fee is fixed, they have no incentive to push high-cost medications. Their goal aligns with the employer’s goal: finding the lowest net cost.
• Stable Budgeting: Employers are protected from the “hidden inflation” of spread pricing, leading to more predictable health plan spend.

How SHARx Drives Expense Optimization

SHARx helps brokers and employers bypass the pitfalls of spread pricing by implementing a procurement model built on transparency. By unbundling high-cost claims from the traditional PBM cycle, SHARx ensures that plan sponsors are no longer victims of the opaque margin.

Through our solution, we empower brokers to deliver:

• Fiduciary Alignment: We do not profit from the spread between pricing benchmarks. Every cent of cost reduction achieved through our procurement solution remains with the client.
• Direct Sourcing: SHARx bypasses traditional markups by focusing on direct procurement strategies that target the actual net cost of lifesaving medications.
• Verified Oversight: We provide the clinical and financial data necessary to prove that the plan is operating with total integrity.

The Takeaway

The choice between spread pricing and cost-plus pricing is ultimately a choice between opaque profit and transparent value.

• Spread Pricing thrives on complexity and hidden margins, often leading to higher long-term costs for employers and members.
• Cost-Plus Pricing prioritizes the fiduciary health of the plan, ensuring that transparency is a measurable reality rather than a marketing buzzword.

By moving toward a transparent, advocacy-driven model, brokers can stop managing “discounts” and start delivering real expense optimization.